 PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTIONS BETWEEN THE CHOLESTEROL-LOWERING EZETIMIBE AND THE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR EFAVIRENZ DURING CHRONIC TREATMENT IN HEALTHY VOLUNTEERS WITH REFERENCE TO INTESTINAL EXPRESSION OF CYP3A4, UGT1A1, ABCB1 AND ABCC2: 